Currently, there are 151.59M common shares owned by the public and among those 102.99M shares have been available to trade.
The company’s stock has a 5-day price change of 0.07% and -13.98% over the past three months. BRKR shares are trading -21.27% year to date (YTD), with the 12-month market performance down to -21.53% lower. It has a 12-month low price of $48.07 and touched a high of $94.86 over the same period. BRKR has an average intraday trading volume of 1.43 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.27%, 0.64%, and -14.55% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Bruker Corp (NASDAQ: BRKR) shares accounts for 78.89% of the company’s 151.59M shares outstanding.
It has a market capitalization of $8.77B and a beta (3y monthly) value of 1.18. The stock’s trailing 12-month PE ratio is 27.86, while the earnings-per-share (ttm) stands at $2.08. The company has a PEG of 1.86 and a Quick Ratio of 0.73 with the debt-to-equity ratio at 1.34. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.74% over the week and 3.58% over the month.
Earnings per share for the fiscal year are expected to decrease by -7.48%, and 14.58% over the next financial year. EPS should shrink at an annualized rate of 15.00% over the next five years, compared to 20.48% over the past 5-year period.
Looking at the support for the BRKR, a number of firms have released research notes about the stock. Guggenheim stated their Buy rating for the stock in a research note on December 19, 2024, with the firm’s price target at $72. UBS coverage for the Bruker Corp (BRKR) stock in a research note released on December 10, 2024 offered a Neutral rating with a price target of $66. Goldman was of a view on December 05, 2024 that the stock is Neutral, while Barclays gave the stock Overweight rating on October 15, 2024, issuing a price target of $75. Wolfe Research on their part issued Peer Perform rating on September 30, 2024.
